KRT18 and metabolic dysfunction-associated steatohepatitis: In contrast, 109 subjects had a CK-18-M30 level above 17.75 ng/L, in which 86 subjects were NASH patients, yielding a PPV of 79% and a specificity of 90% (Fig 2A).